Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2016

01-06-2016 | Original Article

Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

Authors: Akimasa Sekine, Hiroaki Satoh, Tomohisa Baba, Satoshi Ikeda, Ryo Okuda, Takeshi Shinohara, Shigeru Komatsu, Eri Hagiwara, Tae Iwasawa, Takashi Ogura, Terufumi Kato

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2016

Login to get access

Abstract

Purpose

There is no established standard regimen for non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD). For them, we performed a pilot study to evaluate the feasibility of chemotherapy with carboplatin and S-1, which are known as cytotoxic drug with rare development of ILD as adverse event.

Methods

A total of 21 chemotherapy-naive NSCLC patients with ILD were prospectively enrolled between March 2009 and September 2011. Every 3 weeks, carboplatin at a dose of AUC 5 on day 1 and S-1 at a dose of 80 mg/m2 daily for 14 days were administered.

Results

The median age at initiating chemotherapy was 67. Histological examination revealed 10 patients (48 %) with adenocarcinoma. Before chemotherapy, partial pressure of arterial O2 (PaO2) was low with a median of 71 Torr on room air. The median number of cycles administered was four, and the overall response rate and disease control rate were 33 and 67 %, respectively. At the time of data cut-off, all patients were deceased. The median progression-free survival (PFS) and median overall survival (OS) periods were 4.2 and 9.7 months. There was no significant difference of PFS and OS according to tumor histology. Acute exacerbation (AE) of ILD following S-1 plus carboplatin occurred in two patients (10 %, 2/21) within first course treatment. However, they were successfully managed with steroid therapy and survived for 7.0 and 8.8 months, respectively, after AE-ILD development.

Conclusions

This is the first prospective study to evaluate the safety and efficacy of S-1 plus carboplatin treatment for NSCLC patients with ILD. This regimen could be a feasible option for NSCLC patients with ILD, regardless of tumor histology. Our results would support to carry out a large-scale clinical trial to confirm the feasibility of this regimen.
Literature
1.
King TE Jr (2005) Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 172(3):268–279CrossRefPubMed
2.
Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Chida K (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14(5):723–728CrossRefPubMed
3.
Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS, Song KS (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17(6):1216–1219CrossRefPubMed
4.
5.
Antoniou KM, Wells AU (2013) Acute exacerbations of idiopathic pulmonary fibrosis. Respir Int Rev Thorac Dis 86(4):265–274
6.
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network I (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176(7):636–643CrossRefPubMedPubMedCentral
7.
Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, Imai H, Taira T, Murakami H, Endo M, Takahashi T (2015) Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75(3):521–526CrossRefPubMed
8.
Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K (1993) Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103(6):1808–1812CrossRefPubMed
9.
Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K (2014) The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemother Pharmacol 74(6):1159–1166CrossRefPubMed
10.
Shukuya T, Ishiwata T, Hara M, Muraki K, Shibayama R, Koyama R, Takahashi K (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30(10):4357–4361PubMed
11.
Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S, Gemma A (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71(1):70–74CrossRefPubMed
12.
Enomoto Y, Kenmotsu H, Watanabe N, Baba T, Murakami H, Yoh K, Ogura T, Takahashi T, Goto K, Kato T (2015) Efficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing interstitial lung disease: a retrospective multi-institutional study. Anticancer Res 35(7):4259–4263PubMed
13.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191CrossRefPubMed
14.
Okamoto I, Fukuoka M (2009) S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 10(4):290–294CrossRefPubMed
15.
Takiuchi H, Ajani JA (1998) Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 16(8):2877–2885PubMed
16.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221CrossRefPubMed
17.
Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853–860CrossRefPubMed
18.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, Group A-G (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820CrossRefPubMed
19.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13):1640–1648CrossRefPubMed
20.
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14(13):1278–1286CrossRefPubMed
21.
Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, Falcone F, Poletti V (2001) Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 18(1):243–245PubMed
22.
Kurakawa E, Kasuga I, Ishizuka S, Yoshida T, Kunisawa A, Minemura K, Utsumi K, Ohyashiki K (2001) Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Jpn J Clin Oncol 31(6):284–286CrossRefPubMed
23.
Shitara K, Munakata M, Koizumi W, Sakata Y (2007) A case of suspected S-1 induced interstitial pneumonia. Gan to kagaku ryoho Cancer Chemother 34(4):619–622
24.
Tada Y, Takiguchi Y, Fujikawa A, Kitamura A, Kurosu K, Hiroshima K, Sakao S, Kasahara Y, Tanabe N, Tatsumi K, Kuriyama T (2007) Pulmonary toxicity by a cytotoxic agent, S-1. Intern Med 46(15):1243–1246CrossRefPubMed
25.
Ueyama Y, Yamamoto D, Yoshida H, Kanematsu S, Nakatake R, Kasahara N, Tanaka K, Shoji T, Okukawa H, Kwon AH (2010) A case of interstitial pneumonitis induced by S-1. Gan to kagaku ryoho Cancer Chemother 37(8):1603–1606
26.
Yamamoto N, Ohshima T, Sato T, Makino H, Kanazawa A, Yamada T, Murakami H, Yukawa N, Nagano Y, Fujii S, Kunisaki C, Tsukahara T, Rino Y, Masuda M, Imada T (2008) A case of interstitial pneumonia after S-1 administration for gastric cancer. Gan to kagaku ryoho Cancer Chemother 35(11):1935–1937
27.
Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T, Kamei H, Takigawa N, Kiura K (2011) An oral fluoropyrimidine agent S-1 induced interstitial lung disease: a case report. World J Clin Oncol 2(7):299–302CrossRefPubMedPubMedCentral
28.
Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28(36):5240–5246CrossRefPubMed
29.
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K (2013) Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol 24(5):1326–1331CrossRefPubMed
30.
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18(2):317–323CrossRefPubMed
31.
Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, Otsuji M, Yoshida S, Shibuya K, Iizasa T, Saitoh Y, Fujisawa T (2003) Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126(4):1141–1146CrossRefPubMed
32.
Miyazaki K, Satoh H, Kurishima K, Nakamura R, Ishikawa H, Kagohashi K, Hizawa N (2010) Interstitial lung disease in patients with small cell lung cancer. Med Oncol 27(3):763–767CrossRefPubMed
33.
American Thoracic S, European Respiratory S (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304CrossRef
34.
Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Webb WR, Idiopathic Pulmonary Fibrosis Study G (2005) High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172(4):488–493CrossRefPubMed
35.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
36.
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171(9):1040–1047CrossRefPubMed
37.
Agarwal R, Jindal SK (2008) Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 19(4):227–235CrossRefPubMed
38.
Ito K, Jin Z (2015) Characteristics of and risk factors for interstitial pneumonia due to TS-1(R) capsule administration-case reviews from a drug use results survey on non-small cell lung cancer patients and spontaneous reports. Gan to kagaku ryoho Cancer Chemother 42(5):595–603
39.
Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S (2010) Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 15(1):88–92CrossRefPubMed
40.
Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T, Endo M, Yamamoto N (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6(7):1242–1246CrossRefPubMed
41.
Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32(3):1103–1106PubMed
42.
Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K (2015) Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 76(1):69–74CrossRefPubMed
43.
Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T (2006) Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 27(1):143–150CrossRefPubMed
Metadata
Title
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study
Authors
Akimasa Sekine
Hiroaki Satoh
Tomohisa Baba
Satoshi Ikeda
Ryo Okuda
Takeshi Shinohara
Shigeru Komatsu
Eri Hagiwara
Tae Iwasawa
Takashi Ogura
Terufumi Kato
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3040-8

Other articles of this Issue 6/2016

Cancer Chemotherapy and Pharmacology 6/2016 Go to the issue

Erratum

Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study

Original Article

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Original Article

YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo

Original Article

Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers

Original Article

A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

Original Article

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits